Condition
Biliary Tract Neoplasms
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
11 shownAgnostic Therapy in Rare Solid TumorsNCT06638931 · 2024-07-16
RECRUITINGTissue Procurement and Natural History Study of Patients With Malignant MesotheliomaNCT01950572 · 2013-09-09
RECRUITINGTucatinib Continuation StudyNCT07768358 · 2026-11-06
NOT_YET_RECRUITINGExploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid TumorNCT07631884 · 2026-06-15
NOT_YET_RECRUITINGStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640 · 2021-07-19
ACTIVE_NOT_RECRUITINGBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsNCT04579380 · 2021-01-11
ACTIVE_NOT_RECRUITINGPreventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid BiopsiesNCT04566614 · 2020-06-18
COMPLETEDCureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician ChoiceNCT02900248 · 2017-10-02
TERMINATEDClinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP MalignancyNCT02784353 · 2016-10-04
COMPLETEDA Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)NCT02821754 · 2016-07-05
COMPLETEDPortal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical OutcomesNCT07252570 · 2004-04-08
COMPLETEDCommon interventions
tucatinibDRUG2CarboplatinDRUG1CetuximabDRUG1CisplatinDRUG1ConventionalBEHAVIORAL1CryoablationPROCEDURE1ctDNA blood samplingOTHER1DurvalumabDRUG1fulvestrantDRUG1LY3537982DRUG1NivolumabDRUG1PembrolizumabDRUG1PemetrexedDRUG1Perioperative rehabilitation programBEHAVIORAL1Provider determinedOTHER1Radiofrequency Ablation (RFA)PROCEDURE1Trans-arterial Catheter Chemoembolization (TACE)PROCEDURE1Transhepatic portal vein stent implantationDEVICE1trastuzumabDRUG1Trastuzumab RezetecanDRUG1TremelimumabDRUG1
Leading sponsors
Trial status mix
COMPLETED4
ACTIVE_NOT_RECRUITING2
NOT_YET_RECRUITING2
RECRUITING2
TERMINATED1
Phase mix
PHASE25
NA1
PHASE11
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.